Claims for Patent: 7,501,484

Summary for Patent: 7,501,484

Title:	Methods and DNA constructs for high yield production of polypeptides
Abstract:	The invention provides an inclusion body fusion partner to increase peptide and polypeptide production in a cell.
Inventor(s):	Williams; James A. (Lincoln, NE), Luan; Peng (Fishers, IN), Xia; Yuannan (Lincoln, NE), Harley; Scott (Pensacola, FL)
Assignee:	Restoragen, Inc (Lincoln, NE)
Application Number:	10/997,078
Patent Claims:	1. A polypeptide comprising in tandem: a) a first region comprising an inclusion body fusion partner having an amino acid sequence comprising SEQ ID NO: 2; and b) a second region not naturally associated with the first region comprising a preselected amino acid sequence selected from the group consisting of amino acids 7-36 of GLP-1 (SEQ ID NO: 31), amino acids 7-36 of GLP-1 (SEQ ID NO: 31) further consisting of an amide linkage at the C-terminus, amino acids 7-37 of GLP-1 (SEQ ID NO: 32), amino acids 7-37 of GLP-1 (SEQ ID NO: 32) further consisting of an amide linkage at the C-terminus, amino acids 7-36 of GLP-1 further consisting of a K to R substitution at position 26 (SEQ ID NO: 33), amino acids 7-36 of GLP-1 further consisting of a K to R substitution at position 26 (SEO ID NO:33) and further consisting of an amide linkage at the C-terminus, amino acids 7-37 of GLP-1 further consisting of a K to R substitution at position 26 (SEQ ID NO: 34), amino acids 7-37 of GLP-1 further consisting of a K to R substitution at position 26 SE ID NO:34 and further consisting of an amide linkage at the C-terminus (SEQ ID NO: 34), amino acids 1-34 of GLP-2 (SEQ ID NO: 35), amino acids 1-34 of GLP-2 (SEQ ID NO: 35) and further consisting of an amide linkage at the C-terminus, amino acids 1-33 of GLP-2 (SEQ ID NO: 36), amino acids 1-33 of GLP-2 (SEQ ID NO: 36) and further consisting of an amide linkage at the C-terminus, amino acids 1-33 of GLP-2 further consisting of an A to G substitution at position 2 (SEQ ID NO: 37), amino acids 1-33 of GLP-2 further consisting of an A to G substitution at position 2 (SEQ ID NO: 37) and further consisting of an amide linkage at the C-terminus, amino acids 1-34 of GLP-2 further consisting of an A to G substitution at position 2 (SEQ ID NO: 38), amino acids 1-34 of GLP-2 further consisting of an A to G substitution at position 2 (SEQ ID NO: 38) and further consisting of an amide linkage at the C-terminus, amino acids 1-44 of GRF (SEQ ID NO: 39), amino acids 1-34 of (SEQ ID NO: 40), amino acids 1-37 of PTH (SEQ ID NO: 41), amino acids 1-84 of PTH (SEQ ID NO: 42), amino acids 27-38 of Amyloid P Component (SEQ ID NO: 43) and further consisting of an amide linkage at the C-terminus, (Tyr0)-Fibrinopeptide A (SEQ ID NO: 44), Urechistachykinin II (SEQ ID NO: 45), amino acids 12-28 of Amyloid .beta.-Protein (SEQ ID NO: 46), amino acids 22-35 of Amyloid .beta.-Protein (SEQ ID NO: 47), camel .beta.-Endorphin (SEQ ID NO: 48), porcine Valosin (SEQ ID NO: 49), and mouse Vasoactive Intestinal Contractor Peptide (SEQ ID NO: 50). 2. The polypeptide according to claim 1, wherein the first region is linked to the N-terminus of the second region. 3. The polypeptide according to claim 1, wherein the first region is linked to the C-terminus of the second region. 4. The polypeptide according to claim 1, further comprising a cleavable peptide linker between the first region and the second region. 5. The polypeptide of claim 4, wherein the cleavable peptide linker can be cleaved by a cleavage agent selected from the group consisting of palladium, cyanogen bromide, Clostripain, Thrombin, Trypsin, Trypsin-like protease, Carboxypeptidase, Enterokinase, Kex 2 protease, Omp T protease, Factor Xa protease, Subtilisin, HIV protease, Rhinovirus protease, Furilisin protease, IgA protease, Human Pace protease, Collagenase, Plum pox potyvirus Nia protease, Poliovirus 2Apro protease, Poliovirus 3C protease, Nia protease, Genenase, Furin Chymotrypsin, Elastase, Subtilisin, Proteinase K, Pepsin, Rennin, microbial aspartic proteases, Papain, Ficin, Bromelain, Collagenase, Thermolysin, Endoprotease Arg-C, Endoprotease Glu-C, Endoprotease Lys-C, Kallikrein and Plasmin. 6. The polypeptide according to claim 4, wherein the cleavable peptide linker is cleaved by a tissue specific protease. 7. The polypeptide according to claim 6, wherein the tissue specific protease is a prostate specific antigen. 8. The polypeptide according to claim 4, wherein the cleavable peptide linker between the first region and the second region is selected from the group consisting of Ala-Phe-Leu-Gly-Pro-Gly-Asp-Arg (SEQ ID NO: 71), Val-Asp-Asp-Arg (SEQ ID NO: 72), Gly-Ser-Asp-Arg (SEQ ID NO: 73), Ile-Thr-Asp-Arg (SEQ ID NO: 74) and Pro-Gly-Asp-Arg (SEQ ID NO: 75). 9. The polypeptide according to claim 1, further comprising a fusion tag. 10. The polypeptide according to claim 9, wherein the fusion tag is a ligand for a cellular receptor. 11. The polypeptide according to claim 10, wherein the fusion tag is insulin. 12. The polypeptide according to claim 9, wherein the fusion tag is a .beta.-gal a GST a CAT a TrpE, a staphylococcal protein A, a streptococcal protein, a maltose binding protein, a starch binding protein, a cellulose-binding domain of endoglucanase A, a cellulose binding domain of exoglucanase Cex, a Biotin-binding domain, a recA, a Flag, a poly(Arg), a Poly(Asp), a Glutamine, a poly(His), a poly(Phe), a poly(Cys), a green fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, a cayenne fluorescent protein, a biotin, an avidin, a streptavidin, or an antibody epitope. 13. The tandem polypeptide of claim 9, wherein the fusion tag is linked to the preselected amino acid sequence. 14. The polypeptide of claim 13, farther comprising a cleavable peptide linker between the preselected amino acid sequence and the fusion tag. 15. The polypeptide of claim 14, wherein the cleavable peptide linker can be cleaved by a cleavage agent selected from the group consisting of palladium, cyanogen bromide, Clostripain, Thrombin , Trypsin, Trypsin-like protease, Carboxypeptidase, Enterokinase, Kex 2 protease, Omp T protease, Factor Xa protease, Subtilisin, HIV protease; Rhinovirus protease, Furilisin protease, IgA protease, Human Pace protease, Collagenase, Plum pox potyvirus Nia protease, Poliovirus 2Apro protease, Poliovirus 3C protease, Nia protease, Genenase, Furin, Chymotrypsin, Elastase, Proteinase K, Pepsin, Rennin, microbial aspartic proteases, Papain, Ficin, Bromelain, Collagenase, Thermolysin, Endoprotease Arg-C, Endoprotease Glu-C, Endoprotease Lys-C, Kallikrein and Plasmin. 16. The polypeptide according to claim 1, further comprising an additional sequence selected from the group consisting of DYKDDDDK (SEQ ID NO: 81) and MASMTGGQQMGR (SEQ ID NO: 83). 17. An amino acid sequence comprising SEQ ID NO: 83 and SEQ ID NO: 2.

Details for Patent 7,501,484

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2022-05-24